Platelet activation plays a central role in triggering and complicating acute coronary syndromes,
especially in case of stent thrombosis and myocardial infarction. On top of aspirin, P2Y12-
inhibitors are successfully used to treat and prevent these events for a duration of one year after an acute
coronary episode or 6 months after drug-eluting stent implantation. However, patients with acute coronary
syndromes remain at heightened risk for recurrent ischemic events after the recommended durations
of P2Y12-inhibitors and therefore, prolonging treatment is often considered in clinical practice.
However, the higher risk for bleeding limits the utility of such approach to a restricted group who is still
poorly defined by available measures. This review aims to discuss potential benefits and highlight important
pitfalls of prolonged treatment with P2Y12-inhibitors, with a focus on ticagrelor, an attractive
reversible P2Y12-inhibitor in patients after myocardial infarction.
Keywords: Bleeding, clopidogrel, late outcomes, PCI, prasugrel, thrombosis, ticagrelor.
Rights & PermissionsPrintExport